1. Anti-infection
  2. HCV
  3. NM107

NM107  (Synonyms: 2'-C-Methylcytidine)

Cat. No.: HY-10468 Purity: 99.23%
SDS COA Handling Instructions Technical Support

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM.

For research use only. We do not sell to patients.

NM107 Chemical Structure

NM107 Chemical Structure

CAS No. : 20724-73-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM[1][2].

IC50 & Target

HCV[1]

Cellular Effect
Cell Line Type Value Description References
BHK-21 EC50
> 100 μM
Compound: Met-Cyt
Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay
Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay
[PMID: 26479028]
BHK-21 EC50
> 100 μM
Compound: Met-Cyt
Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method
Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method
[PMID: 25014745]
BHK-21 CC50
> 100 μM
Compound: 2'-MeCyt
Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay
Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay
[PMID: 22047799]
BHK-21 CC50
> 100 μM
Compound: 2'-MeCyt
Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 27161176]
BHK-21 CC50
> 100 μM
Compound: NM 107
Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method
Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method
[PMID: 25913116]
BHK-21 CC50
> 100 μM
Compound: 2'-C-methyl-cytidine
Cytotoxicity against BHK21 cells by MTT assay
Cytotoxicity against BHK21 cells by MTT assay
[PMID: 22513121]
BHK-21 EC50
16 μM
Compound: 2'-MeCyt
Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay
[PMID: 27161176]
BHK-21 EC50
16 μM
Compound: Met-Cyt
Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method
Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method
[PMID: 25014745]
BHK-21 EC50
16 μM
Compound: 2'-C-methyl-cytidine
Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
[PMID: 22513121]
BHK-21 EC50
16 μM
Compound: 2'-MeCyt
Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
[PMID: 22047799]
BHK-21 EC50
6 μM
Compound: NM 107
Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method
Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method
[PMID: 25913116]
CCRF-CEM CC50
> 100 μM
Compound: 2'C-MeC
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay
[PMID: 28595015]
CCRF-CEM CC50
22 μM
Compound: 2'-C-Me-C; NM-107
Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay
Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay
[PMID: 30653317]
CCRF-CEM IC50
54.4 μM
Compound: NM-107
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
[PMID: 22014549]
Huh-5-2 CC50
> 33 μM
Compound: 2'-C-Methylcytidine
Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay
Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay
[PMID: 18625766]
Huh-5-2 EC50
2 μM
Compound: 2'-C-Methylcytidine
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay
[PMID: 18625766]
Huh-7 CC50
> 10 μM
Compound: 2'C-MeC
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay
[PMID: 28595015]
Huh-7 CC50
> 10 μM
Compound: NM-107
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
[PMID: 22014549]
Huh-7 CC50
> 100 μM
Compound: 2'-C-Me-C; NM-107
Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay
Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay
[PMID: 30653317]
Huh-7 CC50
> 100 μM
Compound: 2'-C-MeCyd
Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay
Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay
[PMID: 16107149]
Huh-7 CC50
> 300 μM
Compound: 2'-C-Me-C, NM107
Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days
Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days
[PMID: 21621997]
Huh-7 CC50
> 33 μM
Compound: 2'-C-Me-C
Cytotoxicity against human HuH7 cells after 72 hrs
Cytotoxicity against human HuH7 cells after 72 hrs
[PMID: 21880398]
Huh-7 CC50
> 50 μM
Compound: 2'-C-Me-C
Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days
Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days
[PMID: 19072694]
Huh-7 CC50
> 89 μM
Compound: 2'-C-Me C
Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay
Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay
[PMID: 22578461]
Huh-7 CC50
> 98 μM
Compound: 8a, NM-107
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay
[PMID: 24345201]
Huh-7 CC50
> 98.4 μM
Compound: 1, NM-107
Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay
Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay
[PMID: 21033671]
Huh-7 EC50
0.23 μM
Compound: NM107
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
0.48 μM
Compound: NM107
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
0.62 μM
Compound: NM107
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
1 μM
Compound: NM107
Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
1.1 μM
Compound: NM107
Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
1.23 μM
Compound: NM-107
Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay
Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay
[PMID: 18285474]
Huh-7 EC50
1.3 μM
Compound: NM107
Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
1.7 μM
Compound: 2'-C-Me-C, NM107
Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days
Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days
[PMID: 21621997]
Huh-7 EC50
11.2 μM
Compound: 2CMC
Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method
Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method
[PMID: 26988299]
Huh-7 EC50
1143 nM
Compound: NM107
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis
[PMID: 18936191]
Huh-7 EC50
1623 nM
Compound: NM107
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis
[PMID: 18936191]
Huh-7 EC50
2.4 μM
Compound: 2'-C-Me-C
Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay
Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay
[PMID: 21880398]
Huh-7 EC50
2.5 μM
Compound: NM107
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay
[PMID: 18694956]
Huh-7 EC50
2.5 μM
Compound: 19
Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay
Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay
[PMID: 25650256]
Huh-7 EC50
2.8 μM
Compound: NM-107
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
[PMID: 22014549]
Huh-7 EC50
2.8 μM
Compound: 19
Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay
Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay
[PMID: 25650256]
Huh-7 EC50
3.5 μM
Compound: 2'-C-Me-C
Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay
Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay
[PMID: 19072694]
Huh-7 EC50
4.07 μM
Compound: 2'-C-Me C
Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs
Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs
[PMID: 22578461]
Huh-7 EC50
4.6 μM
Compound: 8a, NM-107
Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay
Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay
[PMID: 24345201]
Huh-7 EC50
4.6 μM
Compound: 1, NM-107
Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay
Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay
[PMID: 21033671]
Huh-7 CC50
94.75 μM
Compound: 2CMC
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 26988299]
MT4 CC50
> 98.4 μM
Compound: 1, NM-107
Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay
Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay
[PMID: 21033671]
PBMC CC50
> 100 μM
Compound: 2'C-MeC
Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay
Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay
[PMID: 28595015]
PBMC IC50
47.4 μM
Compound: NM-107
Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
[PMID: 22014549]
PBMC CC50
60 μM
Compound: 2'-C-Me-C; NM-107
Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay
[PMID: 30653317]
Vero CC50
> 100 μM
Compound: 2'-C-Me-C; NM-107
Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay
Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay
[PMID: 30653317]
Vero CC50
> 100 μM
Compound: 2'C-MeC
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay
[PMID: 28595015]
Vero IC50
> 100 μM
Compound: NM-107
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis
[PMID: 22014549]
Vero EC50
18 μM
Compound: 2'-C-methyl-cytidine
Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining
Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining
[PMID: 26119992]
Vero EC50
7.3 μM
Compound: 2'-C-methyl-cytidine
Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining
Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining
[PMID: 26119992]
Vero EC50
94 μM
Compound: 2'-CMC
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay
[PMID: 22310228]
Vero 76 CC50
> 100 μM
Compound: 2'-C-methyl-cytidine
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining
[PMID: 26119992]
Vero 76 CC50
16 μM
Compound: Met-Cyt
Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
[PMID: 26479028]
In Vitro

NM107 (25 μM; 24 hours; Huh7-1 cells and cell culture-propagated HCV) treatment decreases extracellular viral titers and intracellular RNA levels.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR[2]

Cell Line: Huh7-1 cells and cell culture-propagated HCV (HCVcc)
Concentration: 25 μM
Incubation Time: 24 hours
Result: Extracellular virus titers declined in parallel with intracellular RNA levels.
Molecular Weight

257.24

Formula

C10H15N3O5

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H]1[C@@H](O)[C@](O)(C)[C@H](N2C(N=C(N)C=C2)=O)O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (388.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 50 mg/mL (194.37 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.8874 mL 19.4371 mL 38.8742 mL
5 mM 0.7775 mL 3.8874 mL 7.7748 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.72 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.72 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 50 mg/mL (194.37 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.8874 mL 19.4371 mL 38.8742 mL 97.1855 mL
5 mM 0.7775 mL 3.8874 mL 7.7748 mL 19.4371 mL
10 mM 0.3887 mL 1.9437 mL 3.8874 mL 9.7186 mL
15 mM 0.2592 mL 1.2958 mL 2.5916 mL 6.4790 mL
20 mM 0.1944 mL 0.9719 mL 1.9437 mL 4.8593 mL
25 mM 0.1555 mL 0.7775 mL 1.5550 mL 3.8874 mL
30 mM 0.1296 mL 0.6479 mL 1.2958 mL 3.2395 mL
40 mM 0.0972 mL 0.4859 mL 0.9719 mL 2.4296 mL
50 mM 0.0777 mL 0.3887 mL 0.7775 mL 1.9437 mL
60 mM 0.0648 mL 0.3240 mL 0.6479 mL 1.6198 mL
80 mM 0.0486 mL 0.2430 mL 0.4859 mL 1.2148 mL
100 mM 0.0389 mL 0.1944 mL 0.3887 mL 0.9719 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NM107 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NM107
Cat. No.:
HY-10468
Quantity:
MCE Japan Authorized Agent: